Ready to Rumble: HHR May 4, 2025

The latest HHR is here. Ready to Rumble: HHR May 4, 2025. Have you read it? We’re ready to Rumble!

The Department of Justice squares-up on medical journals over pandemic-era fraud, and the Department of Health and Human Services now requires all new vaccines to include placebo trials.

Just waiting for you

**HHS to Require Placebo Trials for all New Vaccines **

DOJ Squares-up on Medical Journals****

Just Say No to REAL ID?****

Coming Soon! Stream each panel discussion from IMA’s Honest Medicine: Redefining Health** conference held in Atlanta**

‘The IMA Feels Like Home’

The Rise of Myocarditis in Young Men****

I Am Big (It’s the Budget that got Small)****

Metabolic Warfare Targeting Tumors******

Tell us what you think. What resonated? What didn’t really?

As far as I’m concerned, ALL vaccines new and old should be required to have placebo trials now!

Personally I would like to see every vaccine and every prescription drug required to post a number of specific numeric values for important considerations for consumers. It should be standardized in an easy to understand format. Minimum examples would be: Efficacy Rate = x%, Risk Ratios divided into categories like: Death = a%, Cardio/Vascular = b%, Renal/Urological = c%, Pulmonary = d%, Neurological = e%, etc. By now there should be plenty of long term data to provide this type of information to the public. Data sheets that come with drugs are totally useless for the common person. If you read through the various contraindications you will often come across one that includes the risk of “death.” So why would anyone take such a medication if one of the potential side effects is death. What would be more helpful is the relative risk of death from studies with a specific number and some sort of comparison with potential benefit. Data sheet that are 17"x22" printed two sides in 8pt type is totally useless to consumers. One of the initiatives of the new administration should be a revamping of the drug data sheets to standardize and simplify the information that is actually useful to the consumer. All the boilerplate disclosures that the lawyers feel necessary should be posted on the company website for those interested in reading it there. But keep the data sheet simple and valuable to the consumer. Unfortunately this is probably wishful thinking on my part given the nature of the priorities of the FDA.

:+1: Agree, agree.

:+1: And completely agree again.